Summer 2024 Prime Therapeutics Report - Prime Therapeutics
Summer 2024 Prime Therapeutics Report
Pulmonary arterial hypertension: Exciting new approval and payer impact
The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. This issue’s cover story (Page 11) explores exciting treatment advances in pulmonary arterial hypertension (PAH), including the first approval of a therapy indicated for PAH. We address how payers may focus and strategize in this category.
Other Summer issue highlights:
New drugs and strategies to treat PNH, PAH, NASH and MS
Upcoming IRA provisions and their impact on your business and members
Star Ratings measures and how you can maintain or boost your results
Insights to help tackle the obesity epidemic with holistic solutions
AI implications for health care
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.